Presentation Information
[S05-06]Progress in creating effective strategies for the control and elimination of leishmaniasis.
Kamaleshwar P Singh1, Swarnendu Kaviraj1, Sreenivas Gannavaram2, Abhay R Satoskar3, Shaden Kamhawi4, Shinjiro Hamano5, Greg Matlashewski6, Hira L Nakhasi 7, ○Sanjay Singh8 (1. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India (India), 2. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 3. Department of Pathology and Microbiology, Ohio State University, Columbus, OH , USA (United States of America), 4. Vector Molecular Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, NIH, Rockville, Maryland, 20852, USA (United States of America), 5. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan. (Japan), 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada (Canada), 7. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA (United States of America), 8. Gennova Biopharmaceuticals, Hinjawadi Phase II, Pune, Maharashtra, India, (India))
Password required to view
Comment
To browse or post comments, you must log in.Log in